New EU Action Plan to Focus Actions Against Antimicrobial Resistance

The action plan takes a One Health approach and addresses AMR in bacteria from humans, animals, and in the environment.

The European Commission has issued new EU guidelines on the prudent use of antimicrobials in human health, based on a proposals prepared by the European Centre for Disease Prevention and Control (ECDC) with input from EU Member States’ experts and stakeholders, and a new action plan to address antimicrobial resistance (AMR) also has been released. It builds on a previous action plan published in 2011 and lists actions to increase surveillance and reporting, boost research about the problem, and adopt an EU strategic approach to pharmaceuticals in the environment.

Earlier this year, the commission set up an AMR One Health network of government experts in human health, animal health, and environmental protection to share ideas and build consensus on next steps.

The commission will enhance its support to Member States to deliver innovative, effective, and sustainable responses to AMR. Specific actions included in the plan build on three main pillars:

  • Making the EU a best practice region: There are significant differences between EU countries in the extent to which effective national policies dealing with AMR have been implemented; the commission aims to support all EU Member States to raise their level to match those of the highest-performing countries.
  • Boosting research, development, and innovation: Actions in this pillar aim to provide valuable input for science-based policies and legal measures to combat AMR, and to address knowledge gaps.
  • Shaping the global agenda: The aim here is to promote EU research efforts and initiatives on AMR on an international level.

"ECDC welcomes this renewed effort to tackle the increasing threat posed by antimicrobial resistance and highlights once more its commitment to support both the European Commission and the EU Member States in their initiatives to address this issue," said ECDC Director Dr. Andrea Ammon. "It's not too late to turn the tide on antimicrobial resistance, but we need to make sure that we act now."

On July 8, the new WHO director-general, Dr. Tedros Adhanom Ghebreyesus, cited AMR as one of the world's major health concerns. Speaking at the G20 meeting in Hamburg, Germany, he said "pandemics of infectious diseases and other threats to health, such as anti-microbial resistance, transcend borders and national interests, so vulnerability for one is vulnerability for all of us. And viruses actually do not know or do not respect borders." He added, "we are not well prepared -- we are very often reactive rather than proactive. Therefore we require a strong global response- that we need to remain connected in our inter-connected world."

Product Showcase

  • Matrix's OmniPro Vision AI Collision Avoidance System

    OmniPro Vision AI is a state-of-the-art collision avoidance system that features NIOSH award-winning Visual Artificial Intelligence (AI) technology. This highly accurate, powerful system identifies and alerts on pedestrians, vehicles and specified objects, ensuring safer facilities, mining operations and industrial sites. With its web-based cloud application, OmniPro Vision AI also logs and analyzes a wide range of data related to zone breach notifications. Operating without needing personal wearable devices or tags, OmniPro has visual and audible zone breach alerts for both operators and pedestrians. Read More

  • Magid® D-ROC® GPD412 21G Ultra-Thin Polyurethane Palm Coated Work Gloves

    Magid’s 21G line is more than just a 21-gauge glove, it’s a revolutionary knitting technology paired with an advanced selection of innovative fibers to create the ultimate in lightweight cut protection. The latest offering in our 21G line provides ANSI A4 cut resistance with unparalleled dexterity and extreme comfort that no other 21-gauge glove on the market can offer! Read More

  • SwabTek® Cannabis Test Kit

    The SwabTek® Cannabis Test Kit is a single-use spot test designed for use in screening for cannabis compounds in any sample type or on any surface. The test is capable of identifying the presumed presence of cannabinoids in very small quantities, with a level of detection as little as 6 μg in mass. Learn more about the SwabTek® Cannabis Test Kit and the rest of SwabTek surface drug testing solutions through the webinar titled "Everything You Want To Know About Surface Testing" Read More

Featured

Artificial Intelligence